Active Ingredient History

  • Now
Lanicemine (AZD6765) is a low-trapping NMDA receptor antagonist that was under development by AstraZeneca for the management of severe and treatment-resistant depression. Lanicemine differs from ketamine in that it is a low-trapping NMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects. However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.   Wikipedia

  • SMILES: N[C@@H](Cc1ccccn1)c2ccccc2
  • Mol. Mass: 198.27
  • ALogP: 2.32
  • ChEMBL Molecules:
More Chemistry
azd6765 | azd-6765 | lanicemine


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue